Thelansis

Gastroesophageal cancer is the second most commonly diagnosed type of cancer and is responsible for more than 1.2 million deaths yearly. Adenocarcinoma is the predominant type of gastroesophageal cancer, comprising 60% to 95% of all malignant tumors. With 5-year survival rates under 30%, the prognosis of gastroesophageal cancer remains poor. HER2 positivity occurs in 15% to 30% of gastroesophageal adenocarcinomas. Gastric cancer is often diagnosed at an advanced stage, defined as unresectable locoregional or metastatic disease, which has a very poor prognosis with 5-year survival not exceeding 5–20%. Systemic chemotherapy remains the mainstay of first-line therapy, with two or three-drug combinations of fluoropyrimidine and a platinum compound, as well as docetaxel and irinotecan, being widely used.   Thelansis’s “HER2 Positive Gastroesophageal Adenocarcinoma (GEA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overvi...

 Gastroesophageal cancer is the second most commonly diagnosed type of cancer and is responsible for more than 1.2 million deaths yearly. Adenocarcinoma is the predominant type of gastroesophageal cancer, comprising 60% to 95% of all malignant tumors. With 5-year survival rates under 30%, the prognosis of gastroesophageal cancer remains poor. HER2 positivity occurs in 15% to 30% of gastroesophageal adenocarcinomas. Gastric cancer is often diagnosed at an advanced stage, defined as unresectable locoregional or metastatic disease, which has a very poor prognosis with 5-year survival not exceeding 5–20%. Systemic chemotherapy remains the mainstay of first-line therapy, with two or three-drug combinations of fluoropyrimidine and a platinum compound, as well as docetaxel and irinotecan, being widely used. Thelansis’s “HER2 Positive Gastroesophageal Adenocarcinoma (GEA) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease over...